Keros Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Keros disclosed a December 2024 exclusive global license agreement with Takeda for elritercept (KER-050): $200M upfront payment, plus potential development ($90M), approval ($280M), and sales milestones ($740M), with tiered royalties in the low double-digits to high teens. The company also presented Phase 1 data for rinvatercept (KER-065) in DMD showing improved lean muscle, bone density, and fat reduction; a Phase 2 DMD trial (~24 patients) is underway with initial data expected H1 2027; and a Phase 2 ALS trial design is planned for regulatory engagement in H2 2026.
Why this rating
Takeda deal is ~44% of company market cap (upfront only), materially de-risks elritercept; Phase 1 data supportive. Not transformational alone but significant financing + validation event.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.